High tide welcomes health canada's steps to create regulatory pathway regarding the use of non-prescription cbd products

Company's existing international cbd brand portfolio positions it well to service canadian wellness market calgary, ab , july 29, 2022 /prnewswire/ - high tide inc. ("high tide" or the "company") (nasdaq: hiti) (tsxv: hiti) (fse: 2lya) a leading retail-focused cannabis company with bricks-and-mortar as well as global e-commerce assets, welcomes the decision by health canada to begin consultations and gather stakeholder feedback regarding the development of a potential regulatory pathway that would permit cannabidiol ("cbd") as a medicinal ingredient in certain health products, regulated under the food and drugs act (canada), which would not require a prescription. the consultation will seek input on regulatory or policy changes pertaining to non-prescription health products containing cbd, including those intended for human use and/or animal use.
HITI Ratings Summary
HITI Quant Ranking